-
Study aim
-
The effects of vitamin B12 supplementation in diabetic peripheral neuropathy
-
Design
-
A total of 40 participants will be recruited and randomly assigned to 2 groups with a 1:1 allocation ratio. Random assignment will be done via block randomization.
-
Settings and conduct
-
Patients will be prescreened by telephone or face-to-face interview at 1 clinical of diabetes in Endocrinology and Metabolism Research Center (Tehran University of Medical Sciences, Tehran, Iran). All of investigators and patients involve will be masked to the treatments assignments until the study will be completed.
-
Participants/Inclusion and exclusion criteria
-
To be eligible for the study, patients will be satisfy the following criteria: male or female patients between 30 and 70 years of age, a MNSI 2 or higher, abnormal NCS, normal folate levels and low vitamin B12 levels. The main exclusion criteria from the study will be as follows: uncontrolled diabetes (HbA1c>9%), history of alcohol abuse, current smoker, current pregnancy or lactating women, diabetic foot , mental disease, heart failure, cancer, evidence of liver disease, impaired renal (GFR < 30)
-
Intervention groups
-
The patients will be received 1 capsule of 1000 mcg of vitamin B12 or 2 capsule of identical-looking two times daily for 4 months.
-
Main outcome variables
-
The primary endpoint was patient-reported neuropathy screening instrument (MNSI), and Neuropathy disability score (NDS) changes at 4 months.